An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

"Dose formulation: open-label vial~Dose level: 7.4 GBq (200 mCi) ± 10% Once, every 6 weeks for 6 cycles, intravenous administration"

"Dose formulation: tablet/capsule~Dose level: 160 mg (four 40 mg or two 80 mg soft capsules) as a single daily dose, oral administration"

"Dose formulation: tablet~Dose level: 1000 mg daily (two 500 mg tablets or four 250 mg tablets as a single daily dose together with 5 mg oral prednisone 2 times a day, oral administration"